Targeted therapy for skin lymphoma using a new immunotoxin
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
This study is testing a new treatment for cutaneous T-cell lymphoma (CTCL) that uses a special therapy to help your immune system fight the cancer more effectively, and it could be a great option for patients whose CTCL hasn't responded to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rock Immune, INC. NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project ID | NIH-10850989 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for cutaneous T-cell lymphoma (CTCL), a type of skin cancer characterized by malignant T lymphocytes causing skin lesions. The approach involves a bispecific immunotoxin that targets specific markers on cancer cells, aiming to enhance the immune response against the tumor. The therapy has shown promising results in preclinical models, significantly improving survival rates compared to existing treatments. Patients with refractory or recurrent CTCL may benefit from this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with refractory or recurrent cutaneous T-cell lymphoma who have not responded well to existing treatments.
Not a fit: Patients with early-stage cutaneous T-cell lymphoma or those who have not been diagnosed with this specific type of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with cutaneous T-cell lymphoma, potentially leading to better outcomes and improved quality of life.
How similar studies have performed: Other research has shown success with similar immunotoxin approaches in treating various cancers, indicating potential for this novel therapy.
Where this research is happening
Denver, United States
- Rock Immune, INC. — Denver, United States (Active)
Researchers
- Principal investigator: Wang, Zhirui — Rock Immune, INC.
- Study coordinator: Wang, Zhirui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.